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Abstract
”Endotoxin and mycoplasma are Nature’s darkest secrets. If they are ever
solved, Hell itself will open.” – Lewis Thomas 1
Endotoxin, or lipopolysaccharides (LPS), are heterogeneous components from
the cell wall of Gram-Negative bacteria and a common challenger in the field
of drug discovery. In challenge studies a system is provoked by a challenger,
such as LPS, which is a commonly used design when studying respiratory and
immune-mediated diseases. Unfortunately, LPS challenge experiments with
the purpose of determining the inhibiting effect of a drug on a biomarker, such
as tumour necrosis factor alpha (TNFα), gives complex data from which it is
difficult to determine the drug effect. This thesis is based on three papers and fo-
cuses on the complexity of TNFα response data from LPS challenge studies and
how mathematical tools can simplify the estimation of the pharmacodynamic
effect of the drug.
The first paper presents a second-generation TNFα turnover model able to
capture TNFα response data from an extensive data set, using the non-linear
mixed effects (NLME) modelling framework. The second paper uses the
developed second-generation model for improvement of the experimental
design in LPS challenge studies, in order to make the TNFα response data
from LPS challenge studies as informative as possible. The third and last paper
describes a user-friendly software package in Mathematica for estimation and
evaluation of NLME models, called NLMEModeling, where the dynamical
systems can be described either as ordinary or stochastic differential equations.
Keywords: Tumour necrosis factor alpha (TNFα), lipopolysaccharides (LPS),
pharmacokinetics and pharmacodynamics (PK/PD), non-linear mixed effects
modelling (NLME), optimal design
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I. Refined and analysed the existing model, performed all computational
work – including the implementation and evaluation of the parameter
estimation in Mathematica, evaluated the results by comparing it with
previously published results, interpreted and validated the results from a
biological point of view, created all figures and tables, drafted and edited
the manuscript.
II. Summarised the literature for an overview of the research field, per-
formed all computational work – including implementation of model
simulations in Mathematica and optimal design in R, evaluated the re-
sults by comparing it with previously published results, interpreted and
validated the results from a biological and practical point of view, created
all figures and tables, drafted and edited the manuscript.
III. Code developing for improvements of model evaluation tools in
NLMEModeling package, edited the manuscript.
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Mathematical modelling within drug discovery is an expanding field and an
important tool for analysing biological phenomena [1]. By creating a math-
ematical model with the ability to describe experimental data, for example
time-series data of a drug or biomarker of interest, it opens up new possibil-
ities of how we can study the problem at hand. The model can be used to
simulate data under circumstances that are not feasible from an economical
or ethical stand-point, to better estimate system parameters for more accurate
results, as well as to plan future studies to be as informative as possible [1, 2, 3].
For example, mathematical modelling serves as a good supplement to animal
testing in pre-clinical studies, where insight from both a mathematical and
pharmacological perspective is crucial for a successful outcome [3, 4].
Mathematical modelling becomes especially important when analysing data
from challenge studies. In a challenge study the effect of a drug is tested on
a system provoked by a challenger, and is a commonly used study design in
respiratory and immune-mediated diseases [1]. A well-known challenger is
the lipopolysaccharide (LPS), which are large molecules from the cell wall of
Gram-Negative bacteria [5]. LPS challenge studies are used when studying the
ability of a drug to inhibit biomarkers related to immuno-response, such as
interleukins (IL), nitric oxides (NO), or tumour necrosis factor alpha (TNFα)
which this thesis will focus on [6]. A problem with LPS challenge studies is that
the distinction between the inhibitory effect of the drug from the stimulatory
effect of LPS in immuno-response data is complicated. Firstly, neither the
TNFα response in absence of LPS, nor the LPS concentrations, are measurable
in vivo. Secondly, TNFα response is highly variable between individuals, as a
consequence of the animals reacting differently to the LPS provocation [7, 8].
It thus exists a need to accurately describe immuno-response data from LPS
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challenge studies, as well as optimise the design of experiments to make the
resulting data more informative, for more robust and reliable estimates of the
inhibitory effect of the drug.
These research questions have been addressed in this thesis. In Paper I we
construct a mathematical model for prediction and analysis of TNFα after LPS
challenge doses and drug interventions, using an extensive data set. We base
our model on a previously published model by our group [9] and the aim
with the work is to produce a framework of how to model TNFα response
in LPS challenge studies in vivo and demonstrate its general applicability
regardless of occasion or type of test compound. In Paper II we then use
our model for optimisation of study design for future experiments. The goal
with this work is to show how to optimise the planning of experiments to
maximise the information in a limited data set, as well as provide guidelines
to both modellers and experimentalists on how to study TNFα response data
from LPS challenge studies. Lastly, in Paper III the Mathematica package
NLMEModeling is described in detail, which have been used to construct,
estimate, and validate the chosen model.
1.2 Problem Formulation
The overall aim with this thesis is to better understand in vivo TNFα response
data in pre-clinical LPS challenge studies, using mathematical modelling, and
use that knowledge to improve the estimation of inhibiting drug effect. This is
achieved by, firstly, in Paper I creating and evaluating a mathematical model
describing TNFα response in Sprague-Dawley rats to retrieve reliable estimates
of the drug effect. Secondly, in Paper II we use that model to optimise the
study design of TNFα response to retrieve more informative data for future
experiments. Lastly, in Paper III the different methodologies of parameter
estimation, model simulations, and model evaluation is presented which gives
a good insight of how the results have been retrieved.
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1.3 Thesis Structure
Chapter 2 introduces relevant topics such as mathematical modelling, param-
eter estimation, model evaluation tools, and optimal study design, in order
to fully appreciate the work done in the appended papers. Chapter 3 then





The term ”mathematical modelling” can have different meaning depending on
the context, but in this thesis the term is used interchangeably with pharmacoki-
netic and pharmacodynamic (PK/PD) modelling. PK/PD models are typically
described using time-dependent ordinary differential equations (ODEs), and
have their roots in compartmental modelling, enzyme kinetics, and chemical
reaction equations [2, 10, 11]. Although the extension to stochastic differen-
tial equations (SDEs) has increased in popularity within the field of PK/PD
modelling, this thesis will only consider PK/PD models using ODEs [12].
The pharmacokinetics of a drug can be described as ”what the body does to
the drug”, while the pharmacodynamics of a drug can be described as ”what
the drug does to the body”, where PK/PD models are mathematical represen-
tations of the phenomena. PK models concerns how the drug concentration
changes over time and how it travels from administration route to its active
site, for example how an oral dose travels to the blood circulation via the gut
(Fig. 2.1). The PD model on the other hand describes the time course of the
drug effect on response, where the response could be biomarkers and receptors,
or functional responses such blood pressure and heart rate [1]. In this simplistic
way of describing a complex biological system one can extract the key character-
istics of the system, for example the clearance (how fast the drug is eliminated),
the bioavailability (the fraction of the drug that reaches the systemic circulation
intact), and the potency (usually quantified by the drug concentration required
to obtain 50% treatment effect, for example 50% inhibition of TNFα response).
In the field of PK/PD modelling, the model building process is characterised
by adding and connecting several models or compartments, that serve as
building blocks with its own specific effect on the model as a whole. A simple








ka ∙ (1-F) ∙ Aab
Figure 2.1: A typical two-compartmental model describing how a per oral dose D0
enters the blood circulation via the gut. Here Agut is the amount of drug in the gut and
Cp the drug concentration in plasma. The parameters are the absorption rate ka, the
bioavailability F , the volume of distribution in plasma Vp, and clearance CL.
would use several building blocks connected to each other, where the model
complexity is dependent of the biological system to be studied and the richness
of the data. Examples of these building blocks are biophase distribution models,
turnover models, direct effect models or signal transduction models. Only a
handful of the available building blocks are presented in this thesis, and for a
review of the most common building blocks, see [2].
2.1.1 Compartmental and Non-compartmental Modelling
PK/PD models can be constructed using either compartmental or non-
compartmental modelling, where compartmental modelling is an established
technique for building models using interconnected compartments while non-
compartmental modelling more focuses on the mathematical expressions char-
acterising the different types of response. Compartments can be described
as containers containing an amount or concentration of a substance (such as
a drug or response), where a compartment could correspond to a physically
existing entity in the body (gut or plasma) or a more abstract entity (a central
or peripheral compartment) [10, 13]. Each compartment is assumed to be
well-mixed, meaning that the amount or concentration of substance entering
the compartment is instantaneously homogeneously distributed within the
compartment [14]. In compartmental modelling these containers are connected
with different types of flows: External in- and outflow corresponding to a
substance entering or leaving the system, mass transfer of a substance from one
compartment to another, and control signals where the presence of a substance
affects the production or elimination of another substance through either stim-
ulation or inhibition. Note that the substance exerting the control action is not
affected itself.
To demonstrate, the PK model visualised in Fig. 2.1 would translate to a system
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of ODEs described as
dAgut
dt




= ka · F ·Agut − CL · Cp, Cp(0) = 0
(2.1)
where Agut is the amount of drug in the gut compartment and Cp is the drug
concentration in the plasma compartment, respectively. The parameters are the
absorption rate constant ka, the bioavailability F , the volume of distribution
in the plasma compartment Vp, the clearance CL, and the initial drug dose D0.
The flows in this model would be the inflow of drug to the gut compartment,
the mass transfer from the gut to the plasma compartment, and the outflow
from the plasma compartment. For more examples on simple compartmental
models, see [1].
The same PK model can be described using non-compartmental modelling,
where the observed system is instead viewed as a sum of exponentials rather
than a flow between compartments. The system would in this case be described
as an uncoupled system of ODEs
dx1
dt
= −Ka · x1, x1(0) = A
dx2
dt
= −Ke · x2, x2(0) = A
C(t) = x1(t)− x2(t)
(2.2)
where the variables x1 and x2 do not correspond to any compartment but
together defines the observed concentration in plasma C. The parameters here
are the absorption rate constant Ka, the elimination rate constant Ke and the
concentration constant A. This setting is preferred if the data is unable to distin-
guish CL from Vp, but comes with several drawbacks. Firstly, the information
concerning D0 is not used. Secondly, since equation (2.2) is not described as
a transfer of mass, the concentration C could be negative which would have
otherwise been impossible for a model built by interconnected compartments.
Lastly, and maybe most importantly, equation (2.2) lacks biological interpreta-
tion in comparison to equation (2.1). Therefore, compartmental modelling is in
many cases the superior, but non-compartmental modelling can prove to be
useful if the number of parameters needs to be reduced.
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2.1.2 Turnover Models and Challenge Models
Turnover models, or indirect response models, describe how a drug or treat-
ment can perturb a system response in steady-state, and are often based on
biological phenomena with parameters that have a physiological meaning.
The drug effect could either be reversible (enzyme inhibited by drug where
the drug is eliminated with time) or irreversible (killing of bacteria or tumour
cells with antibiotics or chemotherapy, respectively), where in this thesis only




= kin − koutR(t), R(0) = R0 (2.3)
where R(t) is the response, kin the zero-order input, kout the first-order output,
and R0 the baseline response. In absence of a drug the response is commonly
in steady-state, according to the equation:
dR
dt




From this the system can be perturbed with a drug effect that is either stimula-
tory or inhibitory. Stimulation and inhibition are commonly defined as









where C is the treatment concentration, Smax > 0 and 0 < Imax ≤ 1 are
the maximal stimulatory or inhibitory effect, SC50 and IC50 are the drug
concentration where 50% stimulation or inhibition is achieved (potency), and n
is the Hill coefficient. In the case of indirect responses, the expressions in (2.5)
act multiplicative on either the input kin or output kout in (2.3) that in total
could give four different perturbations of the system, see Fig. 2.2.




Figure 2.2: Schematic representation of an indirect reversible response model, where
the drug effect could be either stimulatory or inhibitory.
Although all four models have their similarities and differences, insight in
how the drug affects the biological system at hand could be very helpful in the
model selection. If the drug, for instance, inhibits an enzyme it is desirable to
know how the enzyme indirectly affects the response, such that a distinction
between for example inhibition on input from stimulation of output can be
made. For more examples of turnover models, reversible or irreversible, as
well as examples of both direct and indirect response models, see [1].
In some cases the input kin in (2.3) is not necessarily constant in time, namely
not a zero-order input, which in turn creates a time-varying baseline. Challenge
studies in general, and TNFα response in LPS challenge studies in particular,
are examples of systems with a time-varying baseline. Since the TNFα response
in absence of LPS is immeasurable, it would correspond to a baseline response
of R0 = 0. However, when a challenger is added to the system it creates a
stimulation of response that can be described by
dR
dt





where all terms are defined in the equations (2.3) and (2.5) above. If an in-
hibiting drug is simultaneously given with the challenger, either an inhibition
function can act multiplicative on the input or a stimulation function can act
multiplicative on the output, once again dependent on the biological effect of
the drug on the system. For more examples concerning challenge models, see
[15].
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2.1.3 Biophase Models and Transit Compartment Models
Another common trait of TNFα response in LPS challenge studies is that the
response is time-delayed, resulting in an TNFα peak response 1-2h after LPS
administration [16, 17]. To take into account the time-delay, biophase models or
signal transduction models can be used, depending on the duration of the delay.
The biophase model introduces a theoretical effect compartment separate from
the plasma compartment, with the idea that a negligible amount of drug or
challenge enters the effect compartment where the actual effect on response
occurs. In this way a small time-delay is created, while the profile of the drug
or challenge in the plasma compartment remains unchanged [2]. The dynamics
in the effect compartment is modelled as
dCe
dt
= k1eCp − k0eCe (2.7)
where Ce is the concentration of drug or challenge in the arbitrary effect com-
partment, Cp is the concentration in the plasma compartment, and k1e and k0e
are first-order distribution rate constants. The biophase model is also shown
conceptually in Fig. 2.3A.
If an even longer time-delay is required, the transit compartment model is
preferred. The basic idea with the transit compartment model is that the flow
is delayed by bypassing a chain of transit compartments that slows down the
process. The flow between compartments is governed by the mean transit time


















(SN−1 − SN )
(2.8)
where In is an arbitrary input and S1, S2,...,SN is the N number of transit
compartments, see also Fig. 2.3B. For methods determining the number of
transit compartments, see [18]. The transit compartments can be compared
with a biological signalling cascade that in turn leads to response, but each










Figure 2.3: (A) Schematic representation of a biophase model, where the production and
elimination of the drug or challenger in the plasma compartment (Cp) are denoted with
solid arrows, the diffusion from the plasma compartment to the effect compartment is
denoted with a dashed arrow, and the elimination of drug or challenger in the effect
compartment (Ce) is denoted a solid arrow. (B) Schematic representation of the signal
transduction model with transit compartments S1, S2,...,SN and mean transit time τ .
transit compartment does not necessarily need to correspond to physical com-
partments of the cascade [2, 18]. The transit compartment model can also be
interpreted as a simple signal transduction process, although more complex
transduction processes are usually more common.
2.2 Non-Linear Mixed Effects Modelling
In section 2.1 some of the most common building blocks are presented and in
turn how they can be connected to create a PK/PD model. However, although
the PK/PD models are able to capture the key characteristics seen in data, they
lack the ability to describe the different sources of variability in a data set. Since
a drug or treatment is often tested on several test subjects, there will exist an
inter-individual variability based on the fact that every individual responds
differently to a provocation or treatment. Therefore, the ODEs presented in
section 2.1 are extended to non-linear mixed effects (NLME) models, that
allow for different descriptions of the inter-individual variability, as well as the
observation error [19].
Consider a state space model with continuous time dynamics and discrete time
observations that consists of four parts; a system of first order ODEs, an initial




= f(x,u, t,θ), x(t0) = x0(θ)





Here x is a vector of state variables, yj are the observations for each time point
j, t is the continuous time and tj the sampling time points, u is a vector of
system inputs (such as different dosing regimens), θ is a vector of population
parameters, and e(tj) is the independent normally distributed observation
error with zero mean and covariance matrix Σ(x(tj),u(tj), tj ,θ). For examples
of different observation error models Σ, see [20]. The function f(x,u, t,θ)
describes the dynamics of the system with initial condition x0(θ), for example
the PK model presented in Eq. (2.1), while g(x(tj),u(tj), tj ,θ) describes the
observation model, for example the drug concentration in plasma.




= f(xi,ui, t,φi), xi(t0) = xi,0(φi)





where there are only two major differences compared to the original model:
Firstly, an index i = 1, ..., N has been added to all parameters and variables
except the continuous time t, meaning that Eq. (2.10) describes the dynamics of
every individual i in the population. Secondly, the population parameter vector
θ (or equivalently the fixed effects vector) has been replaced by φi, which is a
vector of parameters for each individual according to the relationship
φi = φi(θ,Zi,ηi) (2.11)
where θ is a vector of fixed effects common for all individuals, Zi is a vector
of known individual covariates (such as weight, age etc.), and ηi is a vector of
random effects that are different for each individual. We assume ηi, i = 1, ..., N
are independent and follow a multivariate normal distribution accordingly
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ηi ∼ N (0,Ω) (2.12)
where Ω is the random effects covariance matrix of sizeKxK, whereK denotes
the number of random effects parameters. The matrix is often assumed to
be a diagonal matrix, although correlation between the diagonal elements
is possible. The most common assumptions are that the parameters in φi
are either normally distributed, log-normally distributed, or logit-normally
distributed
φip = θp + ηik, or




1 + exp(−(θp + ηik))
ηik ∼ N (0, ω2k)
(2.13)
for the fixed effects parameter θp, p = 1, 2, ..., P and random effects parameter
ηik with standard deviation ωk, k = 1, 2, ...,K, and for each individual i =
1, 2, ..., N . By describing the variability in data with both inter-individual
variability and observation error (given that data is of population character),
the observation error will decrease relative to the original system in Eq. (2.9) as
well as increase the precision in the estimated parameters, at the cost that the
model complexity increases.
As a last remark on the topic, one can add inter-occasion variability (or inter-
study variability) to the NLME framework. Inter-occasion variability is re-
quired if there exist an apparent difference in the observations in a common
population, where the experiments have been conducted at two different oc-
casions [21]. Although there exist many ways to mathematically consider




θpm · Studym (2.14)
where Studym is either 1 if the individuals are in study group m = 1, 2, ...,M
and 0 else. For more examples of implementation of inter-occasion variability,
see [21].
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2.3 Estimating Model Parameters
After selecting a model structure that captures the key characteristics in a
data set and adding inter-individual variability to the model, using the NLME
modelling framework, the next step is to infer the model parameters from the
experimental data. A common parameter estimation method is the maximum
likelihood approach, where the goal is to find the parameter values such that,
given a statistical model, the observed data is most probable. By defining a
parametrised probalistic model for the data and maximising the likelihood
with respect to the parameters, a maximum likelihood parameter estimate can
be found. However, for most NLME models the likelihood function lacks a
closed-form solution and thus needs to be approximated, where the first-order
conditional estimation (FOCE) approximation and stochastic approximation
expectation maximization (SAEM) are two popular choices [22, 23]. In this
section focus will be on the FOCE approximation of the likelihood function, as
well as optimisation methods used in NLMEModeling [24].
2.3.1 Derivation of the Likelihood Function
The likelihood function is the joint probability distribution evaluated for a set
of given experimental data viewed as a function of the model parameters. For a
statistical model in general, given a data set D and parameters θ, the likelihood
can be defined as:
L(θ|D) , p(D|θ) (2.15)
For NLME models specifically the parameter inference becomes more compli-
cated, since the random effects ηi are unobserved entities. To formulate the
likelihood function removing the dependency of these unobserved entities, the
joint distribution of the data and random effects are marginalised with respect
to ηi, in order to get an expression of the likelihood that is only dependent of
the model parameters θ, Ω, and Σ. After marginalisation with respect to ηi,
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where Di = {di1,di2, ...,dini} is the collection of observations for individual
i = 1, 2, ..., N and observations j = 1, 2, .., ni, and D = {D1,D2, ...,DN} repre-
sents the complete set of observations. If applying Bayes’ theorem on the right






and by noticing that ηi and θ, as well as ηi and Σ, are conditionally indepen-






Since both the observations and random effects are assumed to be normally

























Here εij are the residual errors defined as
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εij = dij − ŷij
ŷij = E[yij |Di(j−1)]
(2.21)
and ŷij is the predicted model output conditioned on the available informa-
tion up to time point ti(j−1) (Di(j−1) = {di1,di2, ...,di(j−1)}). The integral in
Eq. (2.19) with respect to ηi seldom has closed-form solutions. Therefore, the
integral is approximated using a second-order Taylor expansion of li around
the point η∗i that maximises li, which often is referred to the Laplacian approx-
imation [25]. This closed-form expression of the marginalisation yields the















where the log-likelihood has the same maximum as the likelihood, since the
logarithmic function is monotonically increasing. The matrix Hi(η∗i ) is the
Hessian of li evaluated at η∗i , and depending on the number of terms kept in
an approximated expression of the Hessian, the Laplacian method (FOCE), or
the FOCE with interaction (FOCEI) are obtained. For further information, see
[26].
2.3.2 Gradient Based Optimization
The maximum likelihood estimate is obtained my maximising the approximate




where Θ denote the collection of parameters {θ,Ω,Σ}. This can be achieved by,
for example, using a gradient-based optimisation method called the Broyden-
Fletcher-Goldfarb-Shanno (BFGS) algorithm [27]. The BFGS algorithm is a
local optimisation method and belongs to the family of quasi-Newton methods.
Specifically, it is an iterative algorithm for solving unconstrained nonlinear
optimisation problems. In NLMEModeling described in Paper III, the gradient
of the objective function is calculated using an exact method, instead of the
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previous state-of-the-art solution relying on a finite difference approach. For a
derivation of the exact gradients in NLMEModeling, see [26, 28]. To obtain the
uncertainty in the estimated parameters, NLMEModeling uses the variance-
covariance matrix of the estimated parameters, given by the negative inverse
of the Hessian matrix at the optimum. Lastly, the point η∗i , calculated given
the optimal parameter values Θ∗, is the most likely random effects for each
subject. These are referred to as the empirical Bayes estimates (EBEs).
2.4 Model Evaluation Tools
After constructing the model and finding the optimal parameter values, the
next step is to evaluate how well the chosen model represents data. This is done
by using different model evaluation tools for validation of the result. Model
evaluation tools are mainly graphical methods used for data visualisation,
inspection of model adequacy, and assumption testing [29]. There exist a
whole toolbox of graphical methods validating specific model assumptions
and properties, and using only one graphical method is seldom enough to get
a good understanding of how well the model fits data. The graphical methods
of interest, which also are my main contributions to Paper III, are discussed
further below and for a complete list, see [30].
2.4.1 Empirical Bayes Estimates Based Diagnostics
Recall from section 2.3.2 that the point η∗i , calculated given the optimal parame-
ter values Θ∗, are referred to as the empirical Bayes estimates (EBEs). Although
they might be optimal for the given model, it does not necessarily mean that
the assumption that η∗i ∼ N (0,Ω) is fulfilled for all individuals i (see section
2.2). The following three model evaluation tools examine if the assumption
of normality is properly fulfilled, or if there exist unspecified dependencies
between EBEs and other variables in the model. The purpose of each tool
is illustrated using a PK model with two random effects parameters, where
the corresponding EBEs for all individuals i and each random effects k are
henceforth called ηkEBE , k = 1, 2 (see Fig. 2.4).
The first validation tool checks if the elements in ηkEBE truly are sampled from
a normal distribution with standard deviation ωk. This is done by calculating
the η-shrinkage, which is a measure used for comparing ωk estimated in the







where shη is the η-shrinkage, SD(ηkEBE) is the standard deviation of the EBEs
for the specific random effects parameter k, and ωk is the parameter estimated
standard deviation [29]. A low η-shrinkage (SD(ηkEBE) ≈ ωk) is an indica-
tion that the EBEs has been sampled from the assumed distribution. On the
other hand, if shη > 0.2− 0.3 it means that the EBEs has been sampled from
a distribution with a relatively smaller standard deviation (hence the term
”shrinkage”, since the distribution has shrunk in size), and we cannot assume
that the EBEs has been sampled from the correct distribution. Negative values
of the η-shrinkage are also possible (SD(ηkEBE) > ωk) and occur typically with
rich data with small number of subjects, and are a useful signal for possible
model mis-specifications [29]. For an example of a model with low η-shrinkage,
see Fig. 2.4A.
The second validation tool investigates if there exists a dependency between
the EBEs and the individual covariates Zi, thus if all elements in ηkEBE truly
are sampled from a normal distribution with zero mean. This can be visualised
by plotting the empirical distribution of the EBEs as box plots, stratified based
on each covariate [30]. If no dependency exist all box plots should be centred
around zero. However, if there is a dependency there should be a variation in
position and spread for boxplots corresponding to different values of a covari-
ate. This can be used as an indication that a dependency with respect to the
covariates needs to be added to the model [30]. As an example, the clearance of
a drug may be dependent on body weight, where those with high body weight
have a larger clearance than those with low body weight. If this dependency is
not considered in the PK model, the EBEs for the individuals with high body
weight will mainly be positive, while the EBEs for the individuals with low
body weight will mainly be negative as compensation. For an example of a
model without covariate dependency, see Fig. 2.4B.
The third and last validation tool examines if there exist unspecified correlations
between EBEs, in this case between η1EBE and η
2
EBE , in the random effects
covariance matrix Ω (Eq. 2.12). The assumption of no correlation between EBEs
can be checked by calculating the sample correlation coefficient between the
EBEs, as well as visualise the EBEs in a scatter-plot with the different random
effect parameters on each axis, respectively. If the correlation number is high
and a trend in the scatter plot is seen, the random effects are probably correlated.
The problem with correlation can be handled by adding and estimating the
correlation term in the random effects matrix, but only if the data is informative
enough to estimate more parameters. If not, this should be interpreted as an
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Figure 2.4: (A) Normal distribution N (0, ω22) plotted together with the histogram of the
sampled EBEs η2EBE . The estimated and empirical distribution of the EBEs correspond
well with each other, which yields a value of the η-shrinkage of approximately 0.01.
(B) The empirical distribution of η2EBE visualised as box plots, stratified by body
weight. Both box plots centres around zero, indicating that there is no bias. (C) Scatter
plot showing the EBEs for each random effects parameter in the model. A small but
negligible trend is seen between η1EBE and η
2
EBE , and the sample correlation coefficient
is 0.12.
indication of problems in model parametrisation, such as overparametrisation
or non-identifiability of model parameters [30]. For an example of a model
without correlation, see Fig. 2.4C.
2.4.2 Visual Predictive Checks
Visual predictive checks (VPC) is a tool for testing if the chosen NLME model
can reproduce the original data used when constructing the model, with respect
to both the general trend and the variability in data. The most popular version
of VPC is the confidence interval VPC, which is described here, although other
versions exist as well [30]. The confidence interval VPC is constructed by,
firstly, simulating data from the model using the same study design as the
original data (1000 simulated data sets was for example used in [31]). From
this large number of data sets user-defined percentiles are calculated, typically
the 10th, 50th (median), and 90th percentile [30]. Lastly, for each percentile a
nonparametric confidence interval is calculated as a measure of variability of
the percentiles [31]. Finally, the model predicted percentiles and corresponding
confidence intervals are plotted together with the original data, see Fig 2.5.
If a systematic deviation from the original data is seen it could be due to
mis-specifications in either the underlying PK/PD model, the observation
error model, the covariates model, or the implementation of inter-individual
variability. Most importantly, a VPC is easily interpreted in comparison to
other more specific graphical tools, such as EBE based diagnostics.
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Figure 2.5: Confidence interval visual predictive check (VPC) for a PK model with two
different dose groups. The black dots are the original observations, the solid lines are
the 10th and 90th percentile of the original observations (black) and model predicted
observations (grey), and the shaded grey areas correspond to the 95% confidence interval
for each predicted percentile. The data has either been stratified (A), or prediction
corrected (B), and the drug concentrations are shown on a logarithmic scale.
Although VPCs is a good tool for evaluating the overall model performance,
a common problem is the handling of heterogeneous study designs due to
independent variables such as dosing regimens or covariates. One solution is
to stratify the data based on these independent variables, such that one VPC for
each group of individuals corresponding to the same value of the independent
variables is created, see Fig. 2.5A. This method is useful if the data set is rich,
meaning that although the data set is divided into smaller parts, each part
can still sufficiently represent the data as a whole. However, if the data is
sparse such that you are losing information about the population as a whole
if stratifying the data, a more suitable option is the prediction correction VPC.
In prediction correction VPCs the measurements are weighted based on the
independent variables, to retrieve prediction corrected measurements that are
more homogeneous. Prediction correction for every individual i = 1, 2, ..., N
and sampling time point j = 1, 2, ..., ni is done through the equation




where pcYij is the prediction corrected observation, Yij is the observation, lbij is
the lower bound (often set to zero), PREDij is the population model prediction
(the solution to the underlying system of ODEs in a NLME model without
inter-individual variability), and P̃REDbin is the population model prediction
for the median independent variables in a specific bin (where a bin is either
a specific sampling time point or a time interval) [31]. Both the original and
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simulated data are prediction corrected using the population model predictions
according to Eq. (2.25), and the resulting VPC plot is shown in Fig. 2.5B. In
this particular example the lower bound would equal zero, the measurements
for all individuals are taken at the same sampling time points (ni = n, thus no
need for binning), and we have to correct for the two dose groups (small versus
large drug dose). Therefore, the prediction correction of the last measurement





where PREDin is the population model prediction for all individuals who got
the small drug dose, while P̃REDn is the population model prediction for the
median drug dose at sampling time point n (Fig. 2.5).
2.5 Optimal Design
In previous sections it has been discussed how to develop, estimate, and
evaluate a PK/PD model using the NLME framework, but little attention has
been given to what these models are actually based upon - the data. The data
of consideration (drug concentration, biomarker response, heart rate etc.) are
also an important aspect of the model building process, since if the data are
not informative it will be much more difficult to extract the key characteristics
from the biological system of consideration. Therefore, this last section will
give some well-deserved attention to optimal design; how to use mathematical
modelling to design protocols or experiments to retrieve as informative data as
possible (Fig. 2.6).
The essential basis for the optimised planning of an experiment is provided by
the Cramér-Rao inequality. The Cramér-Rao inequality states that the variance-
covariance matrix of any unbiased estimator is bounded by the inverse of the
Fisher information matrix
Cov(q,D,Θ) ≥ I(q,Θ)−1 (2.27)
or, equivalently, that the difference between the variance-covariance matrix
and the Fisher information matrix (Cov(q,D,Θ) − I(q,Θ)−1) is positive-















Figure 2.6: The complete circle of modelling. (A) The model building process starting
with creating a model based on characteristics seen in data, then using a parameter esti-
mation procedure, dependent of the likelihood, to obtain the optimal model parameters.
(B) The optimal design process where the Fisher information matrix, also dependent
of the likelihood, is calculated based on the model with its optimal parameter values.
From this, the optimal design variables can be obtained, that in turn can be used to
produce even more informative data.
{θ,Ω,Σ}, D the observations, and q the design specific variables. Specifically,
q is a collection of different study design related variables such as the sampling
schedule, the number of sampling time points, the dose levels, or the number
of test subjects. The Fisher information matrix is a measure of the amount of











where L(Θ|D) = L(θ,Σ,Ω|D) is the likelihood function defined in Equation
(2.15). In this setting however, compared to section 2.3, the parameters in Θ
are assumed to be fixed to their optimal values, and the variables in q are the
ones being estimated (Fig 2.6) [32].
The goal in optimal design is to find the study design variables q that gives
the highest information content in data, quantified in terms of the Fisher
information matrix. In practice, the size of the Fisher information matrix
is measured in terms of a scalar function called design criterion that maps the
matrix to a scalar number, such that comparisons of Fisher information matrices
are plausible. Several design criteria exist that quantifies the size of the matrix
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differently, but one of the most common design criteria is the D-optimality or





where q∗D is the optimal study design variables and det I(q,Θ) is the objective
function for this specific design criterion. To get lnD-optimality, one takes the
logarithm of the determinant of the Fisher information matrix which provides
higher numerical stability while leaving the optima unaffected [32]. For a
complete list of different design criteria, see [35].
2.5.1 Design Optimisation Procedure
Since the optimisation problem is often multi-dimensional and the objective
function is often non-smooth and non-linear, optimisation of experimental
design is not a trivial task. In addition, simultaneous optimisation of several
different study design variables has been shown to out-perform sequential
optimisation of each study design variable at a time [33], meaning that the
optimisation method needs to be able to handle several different types of
design variables, such as continuous drug dose ranges or discrete sample time
points. To retrieve the results for Paper II the software PopED has been used
for optimisation of design, and the default asymptotically global optimisation
technique for the software will be described further. However, as a limitation
only the optimisation procedure for retrieving the optimal sampling schedule
and continuous variables, such as dose levels, will be discussed. For a complete
list, see [3, 32].
The optimisation procedure starts with defining start guesses and boundaries
for each study design variable that must be feasible and realistic. For example,
the initial and maximum number of measurements must be defined prior
to the estimation, since the obvious solution would otherwise be to have an
infinite number of measurements, which is not realistic. The next step is then to
give the study design variables and corresponding boundaries, together with
appropriate software settings, as input to the algorithm.
The algorithm consists of three separate steps: 1) an adaptive random search
(ARS), 2) a Broyden–Fletcher–Goldfarb–Shanno (BFGS, described in section
2.3) algorithm, and 3) a line search (LS) [32]. Starting with the ARS, it is an
iterative global optimisation method that does not require any calculation of
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the derivative of the objective function. Let OF denote the objective function,
independent of choice of design criteria, and the continuous experimental
variables such as the sampling schedule and dose levels be denoted e. Then
the ARS at iteration k + 1 can be defined as [3]:
ek+1 =
{
ek, if OF (ek + ∆ek) < OF (ek)
ek + ∆ek, if OF (ek + ∆ek) ≥ OF (ek)
∆ek ∼ N (0,S)
(2.30)
Here S is the locality of the random search, defined as a matrix with diagonal
elements equal to the distance between the upper and lower bound for the
specific study design variable in e, divided by a locality factor s [3]. In the
beginning s takes a small value, allowing a search over the whole admissible
domain of the variables, but if the current objective function value remains
unchanged after a certain number of iterations s starts to successively increase.
In this way the neighbourhood at the present optimum is narrowed such that
the result can be refined, hence an adaptive random search [3, 36]. Lastly, if
ek + ∆ek at one iteration is not in the admissible domain it will take the value
at the boundary instead [3]. For example, if the maximal dose level is exceeded
given the current step size, the choice in Eq. (2.30) would be to either stay at
the current dose level or change to the maximal dose level, whatever increases
the objective function value.
The line search in this context should not be confused with the procedure
of consecutively finding the appropriate step size in the descent direction,
which is a more common definition of line search [37]. Here, the LS algorithm
sequentially performs a search in each dimension of the design, for example
each sampling time point or dose level, while keeping the remaining design
variables fix to its current optimum [32, 36]. The admissible domain for each
study design variable is discretized given an either default or user-defined
number of grid points, and the algorithm checks if a change in each and every
study design variable could increase the objective function value.
Lastly, to compare the performance of a study design relative a reference design,
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where q∗ is the current optimal study design variables, q are the study design
variables from the previous iteration (or the initial guess for the first iteration),
and P is the number of model parameters. If the study design variables has
barely changed between two iterations (typically Deff ≤ 1.001), the algorithm
stops [32]. Otherwise it runs through the methods again and calculates the











Figure 2.7: Schematic illustration of the default optimisation technique used in PopED.
The start guesses and boundaries of the study design variables q first enters the adap-
tive random search (ARS) and leaves the ARS when either the maximum number
of iterations is reached or when the objective function value has not changed af-
ter a certain number of iterations. The result from the ARS then enters the Broy-
den–Fletcher–Goldfarb–Shanno (BFGS) algorithm and leaves when convergence is
reached. The result from the BFGS algorithm then enters the line search (LS) and leaves
when the LS has gone through every study design variable. Lastly, the D-efficiency
is calculated to check if the current optimal study design variables q∗ have changed
notably relative q. If not the algorithm stops, and otherwise it runs through the methods
again, starting at the ARS.
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3 Summary of Papers
Paper I: Second-generation TNFα turnover model for improved
analysis of test compound interventions in LPS challenge stud-
ies
This work presents a turnover model describing TNFα release after LPS provo-
cations in absence or presence of anti-inflammatory test compounds, using
NLME modelling. We have constructed a mathematical framework able to
capture both detailed characteristics and general trends, using an extensive
data set together with an extended version of a previously published challenge
model from our team. The goal has been to develop a framework capable of
modelling TNFα response in LPS challenge studies in vivo and demonstrate
its general applicability in model informed drug development for different
types of test compounds and despite inter-occasion variability. What makes
our work stand out from previously published models is the thorough investi-
gation of the LPS-induced stimulation of TNFα response and in turn how it
influences the estimated pharmacological effects, as well as the inclusion of
inter-individual variability through NLME modelling.
For a drug discovery setting, the suggested framework characterises the dif-
ferent sources of variability that is often observed in biomarker responses
after LPS challenge, and enables estimation of pharmacodynamic parameters
(mainly Imax and IC50 values) with good precision. Moreover, the flexible han-
dling of different study designs allows for pooling of data from very different
experimental formats: data from studies with multiple doses of challenger,
multiple doses of test compounds, or different test compounds (including
reference drugs used as positive controls) can be analysed simultaneously.
This extraction and utilisation of data from different sources also helps reduce
the number of animals per study, which is very important for animal welfare
reasons and in a drug discovery setting in general.
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Paper II: Optimizing study design in LPS challenge studies for
quantifying drug induced inhibition of TNFα response: Did
we miss the prime time?
This work uses the model created in Paper I for improvement of the experimen-
tal design in pre-clinical in vivo LPS challenge studies. Since TNFα response
data from LPS challenge studies are very rapid and transient, the data at hand
must be informative to distinguish the key characteristics (such as the inhibit-
ing effect of the test compound) from the variability in data. In this work, we
provide general guidelines of how to optimize the study design for quantifica-
tion of drug induced inhibition of TNFα response in LPS challenge studies, as
well as a summary of how people have conducted these kinds of experiments
in the past.
The study design variables of special interest are the time difference between
LPS and test compound dosing, sampling time points, and initial LPS dose. To
investigate if a more effective inhibition of TNFα response can be achieved by
altering the time difference between system inputs, synthetic data has been
generated by simulation and compared statistically to see if one can observe a
difference in response despite the variability in response. For the remaining
study design related variables the software tool PopED for optimal design,
together with the suggested model from Paper I, has been used to find the
study design variables that maximises the amount of information in data. In
parallel with the optimisation of experimental design, a literature study has
been conducted summarising how LPS challenge studies have been conducted
in the past, giving a broader perspective of how LPS challenge studies are
usually conducted both in a pre-clinical and clinical setting. By using the
recommendations provided in this study the information retrieved from an
initial small pilot study should create sufficient insight to become a robust basis
for designing future pre-clinical and clinical studies and trials, respectively.
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Paper III: NLMEModeling: A Wolfram Mathematica Package
for Nonlinear Mixed Effects Modeling of Dynamical Systems
In this work we present the latest version of the Mathematica package
NLMEModeling developed at FCC, used for parameter estimation of non-
linear mixed effects models described by either ordinary or stochastic differ-
ential equations. The original purpose behind the code base now denoted
NLMEModeling was to provide an efficient proving ground for algorithm
development addressing short comings identified in how gradient based op-
timisation in state-of-the-art NLME software was performed, leading to the
sensitivity based FOCE method or S-FOCE [26, 28]. In addition, there has
been an increasing interest in extending the NLME framework to incorporate
stochastic differential equations, but the software options available for this
class of models were limited. Furthermore, Wolfram Mathematica was found
to be a suitable platform for NLME modelling [38], but no current functionality
for estimation of NLME models existed.
The implemented parameter estimation procedure uses this first-order condi-
tional estimation (FOCE) method to approximate the likelihood function, and a
gradient-based optimisation method called Broyden-Fletcher-Goldfarb-Shanno
(BFGS) algorithm to find the optimal fixed and random effects. In addition,
sensitivity equation-based gradients of the objective function is used instead
of finite differences. For SDEs, the extended Kalman filter is used for calculat-
ing the expected observation values and the corresponding covariance matrix
given data, and the Euler-Maruyama discretisation is used for simulation of
the stochastic differential equations.
In addition to the parameter estimation techniques, several tools are avail-
able for evaluating the result as well as comparing the result with competing
models. Goodness-of-fit plots, diagnostic plots based on the empirical Bayes
estimates (EBEs), and pcVPCs are some examples of the built-in functions for
model evaluation available in the package. In addition, if further evaluation
is required all information concerning the estimation result is provided in the
model object. In summary, NLMEModeling is an user-friendly environment
for estimation and evaluation of non-linear mixed effects models, where the
extension from ODEs to SDEs is seamless.
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4 Outlook
In this thesis TNFα response from pre-clinical LPS challenge studies has been
studied in detail, both how to construct a model describing the response as well
as optimise the study design to retrieve more informative data. In addition,
a software package NLMEModeling has been developed to aid in the model
estimation and evaluation process. Even though several contributions have
been made to the research community, there are always refinements to be done.
After all, modelling is an iterative process. This chapter highlights some of the
improvements that could be made to develop these pieces of research further.
While several models of TNFα response in pre-clinical LPS challenge studies
exist [6, 7, 15, 39, 40, 41], the amount of data used for constructing the model
in Paper I is much larger than for the previous models, to the authors best
knowledge. It would therefore be interesting to make an unbiased compar-
ison of models on new data to explore the different models’ strengths and
weaknesses. For example: Is it possible to fit the model in Paper I to a sparser
data set and still retrieve parameter estimates with acceptable precision? Is
the simplistic model presented in [7] sufficient for the describing the complex
TNFα response? And would a model derived from the biological mechanisms
fit data as good as models using the more classical PK/PD approach [41]?
Answering these questions as well as comparing similarities and differences
between the models would help summarising the field of TNFα response mod-
els, which in turn could lead to better understanding of the reliability of the
pharmacodynamic effect derived from the models.
The comparison of different models on new data would be a part of the model
validation process, where validation of a model is almost as important as the
model building process itself. As an additional part of the validation step,
it would be interesting to conduct new LPS challenge experiments based on
the optimal design proposed in Paper II. This would not only validate the
usefulness of optimal design for TNFα response in LPS challenge studies but
also the model derived in Paper I. Since one of the goals in optimal design is
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to minimise the uncertainty in model parameters, it requires that the chosen
model sufficiently represents data. Using the same reasoning as for the model
comparison, it would be equally interesting to check what the optimal design
would be if using other already existing models for TNFα response in LPS
challenge studies. Lastly, it would be of interest to optimise more study design
parameters, such as the number of sample time points, for further refinement
of the results.
Looking even further, during the course of work resulting in Paper II it was
clear that TNFα response in clinical studies share similar dynamics as the
response in pre-clinical studies. The translation from pre-clinical to clinical LPS
challenge studies has proven to be difficult [42, 43], and it seems there exist a
need for useful tools to facilitate the translation from animals to humans. If
the existing TNFα turnover model could be extended to consider inter-species
scaling, and find an optimal design that suits all species, the results from the
clinical studies could be improved.
To this end the TNFα response model has been defined as an ODE based NLME
model, but an additional extension could be to model the TNFα response
using stochastic differential equations (SDEs). The major problem with TNFα
response in LPS challenge studies has been shown to be the variability in
response, and describing the variability in data with inter-individual variability,
observation error and stochasticity in the system dynamics would potentially
reduce the observation further, compared to the NLME model, as well as
increase the precision in the estimated parameters. Defining the different
sources of variability in response could help understand the underlying biology,
as well as help pinpoint areas in need for improvement of the model.
Moving from ODEs to SDEs would be seamless if using NLMEModeling in
terms of parameter estimation, but more needs to be done concerning SDE
model evaluation. There are currently no evaluation tools that solemnly checks
if the stochasticity is implemented correctly in NLMEModeling. Many of the
available model evaluation tools are not designed to handle the stochasticity
in SDEs, for example the pcVPC. Continuing on the topic of VPCs, a common
trait that has not yet been added to the NLMEModeling package is binning. As
mentioned in section 2.4.2, a bin is either a specific sampling time point or a time
interval, where only the former is currently implemented in NLMEModeling.
Lastly, many of the model evaluation tools should be developed to be more
flexible, to be able to handle the larger variety of models and corresponding
data that is emerging.
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In conclusion, although the appended papers serve as a good contribution
to the research community more work can still be done in the field of TNFα
response in LPS challenge studies in particular, and in the field of parameter
estimation and model evaluation in general. This is turn means that there is
much more to learn about LPS challenge studies which, maybe luckily, means
Hell itself won’t open as Lewis Thomas proposed [44]. At least just not yet.
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